Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 27Neoplasm Metastasis 5Advanced Solid Tumors 5Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors (Excluding Breast Cancer) 2Urologic Diseases 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Refractory Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1

Interventions

pembrolizumab 180Cisplatin 44Paclitaxel 41Carboplatin 41lenvatinib 31Docetaxel 22Pemetrexed 20Fluorouracil 19Capecitabine 16Gemcitabine 15Saline Solution 13Oxaliplatin 13Albumin-Bound Paclitaxel 10epacadostat 9130-nm albumin-bound paclitaxel 9Leucovorin 8Cetuximab 8olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6belzutifan 5Dexamethasone 5enzalutamide 4trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Parkinson Disease 4, Autosomal Dominant Lewy Body × trifluridine tipiracil drug combination × Clear all
NCT05064059 2026-05-26

MK-4280A-007

Merck Sharp & Dohme LLC

Phase 3 Completed
441 enrolled 24 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Merck Sharp & Dohme LLC

Phase 3 Completed
563 enrolled 32 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Merck Sharp & Dohme LLC

Phase 3 Completed
94 enrolled 15 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡